- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00358332
Phase I Pediatric FMP2.1/AS02A Trial in Mali
October 18, 2011 updated by: U.S. Army Medical Research and Development Command
Randomized, Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali
The purpose of this study is to test the safety and dosages of a malaria vaccine in 100 children, 1-6 years old, in Bandiagara, Mali.
The study is testing the safety of the vaccine when it is given to people who are regularly exposed to malaria and it will provide information regarding optimal vaccine dosage.
This study will compare 3 injections of different vaccine doses to a rabies vaccine that is already approved.
During the study, the child's health will be checked in the clinic and during home visits.
Children may participate for about 14 months, and blood will be taken from each child throughout the study.
If the child becomes sick from malaria, he/she will be treated.
Information from this study may be used to develop a malaria vaccine that will help control the disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized, controlled, dose-escalation, phase I trial of the FMP2.1/AS02A
malaria vaccine, using rabies vaccine as a control.
This study is linked to DMID protocol 07-0003.
The primary objective of this study is to evaluate the safety and reactogenicity of FMP2.1/AS02A in children naturally exposed to P. falciparum malaria infection.
The secondary objective is to measure the magnitude and duration of antibody response to FMP2.1 by enzyme-linked immunosorbent assay (ELISA).
One hundred healthy children aged 1-6 years in Bandiagara, Mali, will be randomized to 1 of 3 possible groups.
Twenty subjects will be enrolled in cohort 1 and 40 subjects each in cohorts 2 and 3. Children within each cohort will be randomized in a 3:1 ratio to receive 10, 25 or 50 micrograms of FMP2.1 (in cohorts 1, 2 and 3, respectively) adjuvanted with a proportionate volume of the AS02A, or rabies vaccine.
Thus a total of 75 children will receive the malaria vaccine and 25 the rabies vaccine.
Immunizations will be given on days 0, 30 and 60 in a staggered fashion, with the first administrations of the 25 and 50 microgram dose levels of FMP2.1 following the first administration of the 10 and 25 microgram dose levels, respectively, by 2-3 weeks.
Solicited adverse events will be recorded on the days of immunization and days 1, 2, 3 and 7 after each immunization, and unsolicited adverse events will be recorded for 30 days after each immunization.
Children will be followed for 1 year after the last immunization.
Sera will be collected for anti-FMP2.1 antibody titers on the days of immunization and 14 days after each immunization as well as 3, 6, 9 and 12 months after the first immunization.
Each child will participate in the study for up to 414 days, which includes the screening period.
The primary outcome measures include: occurrence of solicited symptoms after each vaccination during a 7-day surveillance period (day of vaccination and days 1, 2, 3 and 7 after vaccination), occurrence of unsolicited symptoms after each vaccination during a 30-day surveillance period (day of vaccination and 30 subsequent days); and occurrence of serious adverse events throughout the study period.
The secondary outcome measure is titers and activity of anti-FMP2.1 antibody at each time point where serology samples are analyzed, measured by ELISA.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bamako, Mali
- University of Bamako, Malaria Research and Training Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 6 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 1-6 years inclusive at the time of screening.
- Residing in Bandiagara town.
- Appear to be in generally good health based on clinical and laboratory investigation.
- Separate written informed consent obtained from the parent/guardian before screening and study start, respectively.
- Available to participate in follow-up for the duration of study (14 months).
Exclusion Criteria:
- Previous vaccination with an investigational vaccine or a rabies vaccine.
- Use of a investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study immunization, or planned use up to 30 days after the third immunization.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first immunization. This includes any dose level of oral steroids or inhaled steroids, but not topical steroids.
- Confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- Confirmed or suspected autoimmune disease.
- History of allergic reactions or anaphylaxis to immunizations or to any vaccine component.
- History of serious allergic reactions to any substance, requiring hospitalization or emergent medical care.
- History of allergy to tetracycline, doxycycline, nickel or Imidazole.
- History of splenectomy.
- Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than the upper limit of normal of the testing laboratory = 49.6 U/L).
- Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory = 0.5 mg/dL (44.2 micromol/L), or more than trace protein or blood on urine dipstick testing).
- Laboratory evidence of hematologic disease (absolute leukocyte count <5,300/mm^3 or >15,300/mm^3, absolute lymphocyte count <2,300 mm^3, platelet count <133,000/mm^3, or hemoglobin <9.0 g/dL).
- Chronic skin condition that could interfere with vaccine site reactogenicity assessment.
- Administration of immunoglobulins and/or any blood products within the three months preceding the first study immunization or planned administration during the study period.
- Simultaneous participation in any other interventional clinical trial.
- Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition, severe malnutrition, or any other clinical findings that in the opinion of the Principal Investigator (PI) may increase the risk of participating in the study.
- Other condition that in the opinion of the PI would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.
20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
|
FMP2.1 will be reconstituted in AS02A adjuvant.
Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
RabAvert, white, freeze-dried vaccine for reconstitution with diluent.
Dosage: 1.0 mL of rabies vaccine.
|
Experimental: Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.
40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
|
FMP2.1 will be reconstituted in AS02A adjuvant.
Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
RabAvert, white, freeze-dried vaccine for reconstitution with diluent.
Dosage: 1.0 mL of rabies vaccine.
|
Experimental: Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.
40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
|
FMP2.1 will be reconstituted in AS02A adjuvant.
Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
RabAvert, white, freeze-dried vaccine for reconstitution with diluent.
Dosage: 1.0 mL of rabies vaccine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60.
Time Frame: 7 Days following any vaccination
|
The number of participants reporting drowsiness irritability/fussiness, loss of appetite, vomiting, and feverishness.
Participants are counted only once but may have experienced symptoms on multiple occasions.
|
7 Days following any vaccination
|
Occurrence of Unsolicited Symptoms During a 30-day Surveillance Period Following Vaccinations at Days 0, 30, and 60.
Time Frame: Day of vaccination and 30 subsequent days.
|
The number of participants spontaneously reporting any symptom (defined as any Adverse Event considered associated with the product) within 30 days of any vaccination.
Participants are counted only once but may have experienced events on multiple occasions.
|
Day of vaccination and 30 subsequent days.
|
Number of Subjects Spontaneously Reporting Any Serious Adverse Event.
Time Frame: 1 year after the last vaccination.
|
Any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, required in-patient hospitalization or prolongation thereof, was life threatening or a congenital anomaly/birth defect in offspring of a study subject; or may have jeopardized the participant or required intervention to prevent one of the outcomes.
|
1 year after the last vaccination.
|
Occurrence of Solicited Local Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60.
Time Frame: 7 Days following any vaccination
|
The number of participants reporting pain, swelling and erythema.
Participants are counted only once but may have experienced symptoms on multiple occasions.
|
7 Days following any vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 0
Time Frame: Day 0
|
This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA.
|
Day 0
|
Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 30
Time Frame: Day 30 +/- 7 days
|
This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA.
|
Day 30 +/- 7 days
|
Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 60
Time Frame: Day 60 +/- 7 days
|
This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA.
|
Day 60 +/- 7 days
|
Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 90
Time Frame: Day 90 +/- 10 days
|
This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA.
|
Day 90 +/- 10 days
|
Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 180
Time Frame: Day 180 +/- 14 days
|
This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA.
|
Day 180 +/- 14 days
|
Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 272.
Time Frame: Day 272 +/- 14 days
|
This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA.
|
Day 272 +/- 14 days
|
Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 364
Time Frame: Day 364 +/- 14 days
|
This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA.
|
Day 364 +/- 14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
July 27, 2006
First Submitted That Met QC Criteria
July 27, 2006
First Posted (Estimate)
July 31, 2006
Study Record Updates
Last Update Posted (Estimate)
October 24, 2011
Last Update Submitted That Met QC Criteria
October 18, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-0146
- 2U01AI065683-06 (U.S. NIH Grant/Contract)
- U19AI065683 (U.S. NIH Grant/Contract)
- GSKBio: Malaria 051 (106874)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasmodium Falciparum Malaria
-
SanofiMedicines for Malaria VentureCompletedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Uganda
-
Novartis PharmaceuticalsRecruitingUncomplicated Plasmodium Falciparum MalariaCôte D'Ivoire, Kenya, Ghana, Uganda
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesCompletedUncomplicated Plasmodium Falciparum MalariaTanzania
-
SanofiMedicines for Malaria VentureTerminatedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Mozambique, Uganda, Vietnam
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati...CompletedUncomplicated Plasmodium FalciparumIndonesia
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical...RecruitingMalaria, Plasmodium FalciparumGambia
-
PfizerCompletedPLASMODIUM FALCIPARUM MALARIAIndia
-
Centers for Disease Control and PreventionMinistry of Health, LiberiaCompletedMalaria | Plasmodium Falciparum | Uncomplicated MalariaLiberia
-
Muhimbili University of Health and Allied SciencesUppsala University; The Swedish Research CouncilNot yet recruitingUncomplicated Plasmodium Falciparum MalariaTanzania
Clinical Trials on FMP2.1/AS02A
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID); The...Completed
-
U.S. Army Medical Research and Development CommandNational Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaboratorsCompleted
-
U.S. Army Medical Research and Development CommandNational Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaboratorsCompletedMalaria | Plasmodium Falciparum MalariaMali
-
University of OxfordNational Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...CompletedPlasmodium Falciparum MalariaUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
GlaxoSmithKlineCompletedTuberculosis (TB)Switzerland
-
GlaxoSmithKlineCompleted
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaboratorsCompleted
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)Completed